-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Gliosarcoma Drug Details: Pegargiminase (ADI-PEG 20) is under development for...
-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Malignant Pleural Mesothelioma Drug Details: Pegargiminase (ADI-PEG 20) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Pegargiminase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Non-Small Cell Lung Cancer Drug Details: Pegargiminase...
-
Product Insights
Gliosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Gliosarcoma - Drugs In Development, 2023’, provides an overview of the Gliosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Leiomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Leiomyosarcoma - Drugs In Development, 2023’, provides an overview of the Leiomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
United States (US) Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
US Defense Market Report Overview The US defense budget was worth $818.8 billion in 2023, which was a 10.7% rise from the previous year. This is in response to the deteriorating global security environment such as the Russian invasion of Ukraine and continued tensions with China over territory in the South China Sea and wider Indo-Pacific. Numerous geo-strategic and domestic political imperatives continue to drive US expenditure as defense capabilities gain growing political importance. The country’s defense budget is expected to...